HTB

COVID-19

UK RECOVERY study shows no benefit from aspirin in people hospitalised with COVID-19

Reducing the risk of COVID-19 in research that involves interrupting ART

New BHIVA statements on HIV and COVID-19 (December 2021)

Myocarditis and pericarditis after COVID-19 vaccines

WHO advises against use of convalescent plasma for COVID-19

Colchicine: no clinical benefits against COVID-19 in pooled analysis of RCTs

Eli Lilly withdraw EU application for bNAbs etesevimab and bamlanivimab

Reduced responses to COVID-19 vaccines at low CD4 counts

Continued evidence for poorer COVID-19 outcomes in people with HIV  

Immune responses to natural COVID-19 infection in HIV positive people

Durability of immune responses to COVID-19 vaccines in HIV positive people

Sputnik V vaccine not approved in South Africa due to potential increased risk of HIV

Sanofi reports phase 1/2 mRNA results but withdraws from further COVID19 vaccines

Early efficacy results with oral molnupiravir focuses attention on price and access

BHIVA statements on third vaccine doses for people living with HIV

HIV increases risk of severe COVID-19 in largest US study

SARS-CoV-2 variants and immunosuppression

UK vaccine programme saved 100,000 lives

Large US registry confirms safety of COVID-19 vaccines during pregnancy

US FDA grants full approval to Pfizer vaccine

Immune responses against Delta variant in people vaccinated in the UK

Neutralising antibody levels from COVID vaccines correlate negatively with age

Evolution of neutralising antibody responses to natural infection and after vaccination

Outbreak of 469 symptomatic Delta cases in fully vaccinated adults during Bear Week

IAS 2021: WHO report links HIV to 30% increased mortality from COVID-19: based on South African data

Antibody responses to Pfizer vaccine in HIV positive people with high CD4 counts

Third dose of mRNA vaccine improves antibody responses in kidney transplant recipients

US CDC recommends third vaccine dose in some groups

Pfizer plans for third dose: questions over population need?

Efficacy of Oxford/AZ and Pfizer vaccines against Delta variant in the UK

Results from Novavax phase 3 study in the UK

WHO approves Chinese vaccines for emergency use

Selected other vaccine studies

Efficacy of Chinese CoronaVac vaccine in Chile national programme

NHS supports selected use of inhaled budesonide for COVID-19 in people at risk of severe events

Reviews of ivermectin for COVID-19: evidence from RCTs is still needed

RCT shows no impact of azithromycin in reducing symptoms of mild COVID-19

Variation in ACE2 levels are not related to outcomes from COVID-19

London HIV study of responses to COVID-19 vaccines and natural infection (SCAPE)

mRNA vaccine fails to produce antibody response in late-stage HIV: low CD4 count and high viral load

Special report on background incidence of adverse events in vaccine studies

Third vaccine dose increases immune response to 68% in French transplant recipients

Third COVID-19 vaccine dose in US cohort of people on immune-suppressing treatment: safety and ethical issues

Plans for universal third vaccine dose for UK adults from September

COVID-19 vaccines increase sperm quality: potential to help uptake

Research approach to rapidly review candidate treatments for COVID-19: nine studies using ACTIV protocol

COVID-19 treatment: tofacitinib, REGN bNAbs, convalescent plasma

COVID-19 timeline: global events from the last 18 months

Virology Education: monthly forums on COVID-19

COVIDsalon

Resources on Long COVID

Selected presentations at BHIVA: COVID-19, PrEP in the UK, community involvement and more…

No differences in outcomes among women with and without HIV with high-risk pregnancies and COVID-19

HIV associated with higher risk of severe COVID-19 in US cohort

MHRA authorises Janssen/J&J COVID-19 vaccination in the UK

Reduced antibody responses to first dose of mRNA COVID-19 vaccines in HIV positive people with a lower CD4 count

France routinely recommends third dose of COVID-19 vaccine for some people with reduced immune function

US CDC reports 10,000 breakthrough infections after full vaccination: showing success of vaccine programme

Cases of COVID-19 reported including deaths in care home residents after full-course vaccination

Israeli study reports reduced vaccine efficacy in people with immune suppression until 14 days after the second dose

Novavax reports 43% efficacy against B.1.351 South African variant but negative impact in HIV positive participants

Oxford/AZ vaccine linked to 242 rare bloods clots in the UK: alternative recommended for people younger than 40

COVID-19 vaccine candidate from GSK and Sanofi to move to phase 3 placebo controlled study

Meta-analysis of 18 ivermectin studies reports benefit

Asymptomatic infection has similar SARS-CoV-2 viral load to mild COVID-19

Post navigation